Patient Centricity in Clinical Trials: Meaning and How to Test It

In an analysis of 2,542 randomized surgical trials, 54.1% failed to reach their target enrollment [1]. Nearly every CRO and vendor deck now promises a "patient-centric" answer, yet few can name a protocol decision that changed because of it. The test is simple: did patient input arrive before the protocol was locked, and did it alter visits, procedures or endpoints? Below are a working definition, the design decisions in the order a protocol is built, what FDA expects, and a checklist for your plan or a vendor's pitch. Refero does not run recruitment campaigns. We vet and match the clinical research marketing agencies that do, so what follows is written for the buyer, from what those vendors need and see.

Patient-centric clinical trials at a glance

Faster recruitment and better launch odds are associated with patient-centric design, and the burden patients report points at the same levers.

• 54.1% of randomized surgical trials miss their target enrollment [1]
• Drugs developed with patient-centric designs were 19 percentage points more likely to launch in one analysis [2]
• Patient-centric trials took around half as much time to recruit 100 participants in neurology and oncology [2]
• 76% of participants rate home or near-home visits very helpful, the top-ranked of ten services [3]
• Phase III protocols now collect 5.9 million datapoints on average [4]

What patient centricity in clinical trials means

Patient centricity in clinical trials means designing and running a study around what participants can realistically do and what matters to them. Their input sets visit schedules, procedures, endpoints, consent materials and support before the protocol is locked, and the team then checks that the changes show up in enrollment and retention. The idea has been in the literature for a decade. An early review framed patients as informed collaborators whose participation is core to a trial, where older models saw data-generating subjects [5].

Patient-centered care describes how clinicians treat patients in a hospital or practice. Patient centricity in clinical trials describes how a study is designed and run, which is the part a sponsor or CRO lead controls. Readers who search for one often land on the other, so a hospital checklist does not help you audit a protocol.

The term is often dismissed as a buzzword, and the reason is timing. If patients are consulted after the protocol is locked, their input can change brochures, reminder messages and the welcome call. It cannot change the visit schedule, the procedures or the endpoints. Call this the protocol-lock test: input that arrives before lock and changes something in the protocol is practice, and input that arrives after is a label.

Why patient-centric clinical trials matter: what the evidence shows

Patient-centric design is associated with faster recruitment and a higher chance of launch. The strongest figures available come from an observational analysis and should be read that way. A 2019 Economist Intelligence Unit analysis of drugs in phase II and III was commissioned by a contract research organization. It found that drugs developed with patient-centric designs were 19 percentage points more likely to launch, with the gap widest in oncology (37 points), then neurology (31) and rare diseases (11) [2]. In neurology and oncology, patient-centric trials took around half as much time to recruit 100 participants, and in rare disease about a fifth of the time [2].

Those numbers describe association. Sponsors who adopt patient-centric designs may also differ in funding, experience and therapeutic area. Before you quote the numbers to leadership, ask for the underlying report's sample size and its definition of "patient-centric". The direction is still useful, because the mechanism is plausible: fewer reasons to decline or leave means fewer screened people lost.

Time saved at enrollment is worth whatever a delay day costs the sponsor, so weigh the design work against published per-patient and per-delay-day recruitment costs.

Involve patients before protocol lock

Patient input changes a trial only when the schedule, procedures and endpoints can still move, which means before the protocol is final. The common methods fit different points in that timeline. Advocacy organizations and patient advisory boards help at concept stage, when the question is which outcomes and burdens matter in the condition. Focus groups with a mix of participants, including people who declined or left earlier studies, help test the draft design. A patient read-through of the near-final protocol catches the visit, procedure and questionnaire load that looked reasonable on paper.

An illustrative example, not a reported case: a draft protocol calls for weekly site visits for a blood draw and a symptom review. In an advisory session, patients explain that the weekly trip is the reason many would refuse, and that the symptom review needs no examination. The team moves to site visits at set milestones, with home nursing or telehealth in between. That is a changed visit schedule, which is what separates practice from label.

Endpoints are the other decision to take to patients early. Ask which symptoms and functions matter before endpoints are chosen, then decide whether a patient-reported outcome, collected through an app or at the visit, belongs among them. When the condition affects memory, mobility or decision-making, caregivers and disease stage belong in the input group too, because the person at the visit may not be the person with the symptoms.

Cut participant burden in the protocol

Participant burden is countable: site visits, travel time, invasive procedures, questionnaire minutes and out-of-pocket cost, each tallied per visit before the schedule is final. Protocols have been moving the other way. Procedures per participant visit rose 37% over 15 years in the Tufts CSDD and TransCelerate analysis of trial protocols [4], so a team that never audits burden inherits a heavier load each cycle.

Travel is the most fixable item. In a 2025 survey of participants, 24% spent more than an hour getting to a visit each way [3]. Rating ten services, 76% called home or near-home visits very helpful, ahead of transportation (72%), caregiver support (70%) and compensation (68%) [3]. Telehealth visits, home nursing, local labs and wearables are the levers, and the choice depends on which procedures genuinely need a site. How decentralized models affect enrollment speed and dropout varies by model and vendor type, so check that evidence before committing.

Once participants are enrolled, the question becomes why they leave, and the dropout drivers and retention tactics that follow are a separate problem from design.

Consent, support and access built around participants

Consent, support and access are where a protocol either removes reasons to say no or leaves them in place. Plain-language consent means testing the document as well as writing it simply. Run a reading-level check, have a handful of people from the target population explain back what they would be agreeing to, and rewrite what they get wrong. eConsent and lay summaries help when they follow the same test.

Support removes the financial and travel reasons that patients cite. One in three participants in the CISCRP survey received no compensation or reimbursement of any kind [3]. Fast reimbursement, travel help, multilingual materials and a named contact are therefore budget lines to decide before the protocol goes to sites. Access depends on site choice, language and eligibility criteria that exclude people without a scientific reason. If an exclusion cannot be tied to safety or to the question the trial asks, a patient advisory group is a good place to find out.

What regulators expect from patient-centric drug development

FDA's Patient-Focused Drug Development guidance series is where it addresses how patient input should shape development. The series has four parts: collecting comprehensive and representative input, identifying what matters to patients, selecting or modifying fit-for-purpose clinical outcome assessments, and incorporating those assessments into endpoints. Three are final and the fourth is in draft [6]. The order mirrors the design sequence above, which is why a sponsor can use the series as a checklist for protocol decisions.

Other regulators publish their own material: EMA's reflection paper on patient experience data was released as a draft, with consultation closing in January 2026 [7]. Guidance describes an agency's current thinking and is not a binding requirement, so confirm what applies to your product in the agency documents themselves. This is not legal advice; confirm with regulatory counsel and the IRB of record.

How to test whether your trial is patient-centric

A trial is patient-centric when you can point to a protocol decision that patients changed and a measure showing it worked. The checks below are for your own protocol or a vendor's pitch, and each says when to run it.

Run the protocol-lock test before funding anything else

Use this when a plan or deck says "patient-centric" without dates. Ask for the date patient input was gathered, the date the protocol was locked, and one change made as a result. If the input came after lock, treat the work as materials and support, and price it that way.

Count burden per visit and cut what patients would not do

Use this when the schedule is drafted but not final. List every procedure, questionnaire and trip for each visit, ask patients which they would refuse, and remove or relocate those that do not need a site.

Test consent with patients, not just a readability score

Use this when consent documents are written by regulatory or legal teams. Ask for the reading-level result and the teach-back results from a sample of the target population.

Budget support services as line items

Use this when reimbursement, travel and language support are assumed to sit "with the sites". If no one owns the budget, the service will not reach the participant.

Require one patient-relevant endpoint

Use this when endpoints were set by the clinical team alone. Ask which outcome patients said mattered and where it appears in the endpoint hierarchy.

Track four measures and read them at set points

Use this from first-patient-in. Track screen-to-enrollment rate, time to enroll against the protocol's assumption, dropout against the protocol's assumption, and participant feedback scores. Read them at fixed intervals, not only at the end, and set them against enrollment timelines for comparable trials so a slow month is judged against a real benchmark.

Ask a vendor what patients changed and what was measured

Use this when a CRO, recruitment vendor or agency says its services are patient-centric. Ask for one protocol change that came from patient input on a past study, how enrollment or dropout moved afterwards against the original assumption, and who can confirm it. A vendor that can show only a brochure, an app or a concierge line has described logistics added after design.

If you would rather not run that evaluation alone, Refero screens healthcare marketing and patient recruitment agencies against five published criteria and introduces up to three that fit your brief. It is free for buyers, and there is no obligation to hire anyone we introduce. Tell us what you need.

Frequently asked questions

What does a patient-centered clinical trial mean?

A patient-centered trial is one whose design and operations were shaped by input from the people it will enroll. Patients influenced visit schedules, procedures, consent materials and endpoints before the protocol was final, and the sponsor tracks whether those changes improved enrollment and retention. If the input only produced brochures or reminders, the study is better described as supported than as patient-centered.

What is another way to say patient-centric?

Patient-focused, patient-driven and patient engagement are common equivalents, and FDA uses "patient-focused drug development" for its guidance series [6]. They are used loosely, so the useful question is what the speaker changed. A vendor who says "patient-focused" and cannot name a protocol decision is using a different word for the same label.

Why do 90% of clinical trials fail?

Roughly 90% of drug candidates that enter clinical trials never reach approval, according to a 2022 review in Acta Pharmaceutica Sinica B [8]. That review attributes 40% to 50% of failures to lack of clinical efficacy and about 30% to unmanageable toxicity. Recruitment and retention problems cause delay and some terminations, and that is the part patient-centric design can affect. It does not rescue a drug that does not work, so treat any vendor claim otherwise with caution.

How do patient-reported outcomes fit into a patient-centric trial?

Patient-reported outcomes are measures that come directly from the participant, such as symptoms or function, often collected through an electronic app. Patients help choose them by saying which outcomes matter before endpoints are set. FDA's guidance series covers selecting fit-for-purpose clinical outcome assessments and incorporating them into endpoints, which is why regulators take an interest in the data [6].

How is patient centricity different from patient-centered care?

Patient-centered care is about how clinicians treat patients in practice, including shared decisions and respect for preferences. Patient centricity in clinical trials is about how a study is designed and run: what participants are asked to do, which outcomes are measured and how consent and support work. The two share values but a sponsor can only audit the second against a protocol.

Sources

• Shadbolt C, et al. Analysis of Rates of Completion, Delays, and Participant Recruitment in Randomized Clinical Trials in Surgery. JAMA Network Open, 2023. Link
• Economist Intelligence Unit. The Innovation Imperative: The Future of Drug Development (patient-centric trials section), 2019. Link
• CISCRP. 2025 Perceptions and Insights Study: Participation Experiences. Link
• Getz K, et al. Insights Informing Strategies for Optimizing the Collection of Clinical Trial Data. Therapeutic Innovation & Regulatory Science (Tufts CSDD and TransCelerate), 2026. Link
• Sharma NS. Patient centric approach for clinical trials: Current trend and new opportunities. Perspectives in Clinical Research, 2015. Link
• US Food and Drug Administration. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient's Voice in Medical Product Development and Regulatory Decision Making. Link
• European Medicines Agency. Patient experience data (PED) reflection paper, draft for consultation, EMA/CHMP/PRAC/148869/2025. Link
• Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B, 2022. Link